Synthesis of a 2-Aryl-3-aroyl Indole Salt (OXi8007) Resembling Combretastatin A-4 with Application as a Vascular Disrupting Agent
作者:Mallinath B. Hadimani、Matthew T. MacDonough、Anjan Ghatak、Tracy E. Strecker、Ramona Lopez、Madhavi Sriram、Benson L. Nguyen、John J. Hall、Raymond J. Kessler、Anupama R. Shirali、Li Liu、Charles M. Garner、George R. Pettit、Ernest Hamel、David J. Chaplin、Ralph P. Mason、Mary Lynn Trawick、Kevin G. Pinney
DOI:10.1021/np400374w
日期:2013.9.27
and found to be strongly cytotoxic against selected human cancer cell lines (GI50 = 36 nM against DU-145 cells, for example). The free phenol, 8 (OXi8006), was a strong inhibitor (IC50 = 1.1 μM) of tubulin assembly. The corresponding phosphate prodrug 33 (OXi8007) also demonstrated pronounced interference with tumor vasculature in a preliminary in vivo study utilizing a SCID mouse model bearing an orthotopic
天然产物秋水仙碱和考布他汀 A-4 是微管蛋白组装的有效抑制剂,它们激发了大量小分子潜在抗癌药物的设计和合成。基于吲哚的分子支架在这些 SAR 修饰中很突出,导致药物数量迅速增加。2-芳基-3-芳基吲哚基苯酚8 (OXi8006)的水溶性磷酸盐前药33 (OXi8007)通过化学合成制备,发现对选定的人类癌细胞系具有强细胞毒性(GI 50 = 36 nM,对 DU -145 个单元格,例如)。游离苯酚8 (OXi8006) 是一种强抑制剂 (IC 50= 1.1 μM) 的微管蛋白组装。在一项初步的体内研究中,相应的磷酸盐前药33 (OXi8007) 也表现出对肿瘤血管系统的显着干扰,该研究利用带有原位 PC-3(前列腺)肿瘤的 SCID 小鼠模型,如彩色多普勒超声成像所示。这些结果的结合提供了证据,证明基于吲哚的磷酸盐前药33 (OXi8007) 作为血管破坏剂发挥作用,可能被证明可用于治疗癌症。